(Q42210316)

English

Frequent incidence of escape mutants after successful hepatitis B vaccine response and stopping of nucleos(t)ide analogues in liver transplant recipients

scientific article published on October 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Frequent incidence of escape mutants after successful hepatitis B vaccine response and stopping of nucleos(t)ide analogues in liver transplant recipients (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Hepatitis B vaccine

1 reference

based on heuristic

inferred from title

author name string

Masatoshi Ishigami

1

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Takashi Honda

2

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Yoji Ishizu

3

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Yasuharu Onishi

4

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Hideya Kamei

5

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Kazuhiko Hayashi

6

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Yasuhiro Ogura

7

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Yoshiki Hirooka

8

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Hidemi Goto

9

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

publication date

1 October 2014

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Liver Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

1211-1220

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy

1 reference

https://api.crossref.org/works/10.1002%2FLT.23935

21 January 2018

Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results

1 reference

https://api.crossref.org/works/10.1002%2FLT.23935

21 January 2018

Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection

1 reference

https://api.crossref.org/works/10.1002%2FLT.23935

21 January 2018

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

1 reference

https://api.crossref.org/works/10.1002%2FLT.23935

21 January 2018

Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis

1 reference

https://api.crossref.org/works/10.1002%2FLT.23935

21 January 2018

Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FLT.23935

21 January 2018

Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FLT.23935

21 January 2018

HBV vaccination in liver transplant recipients: not an effective strategy in the prophylaxis of HBV recurrence

1 reference

https://api.crossref.org/works/10.1002%2FLT.23935

21 January 2018

Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FLT.23935

21 January 2018

Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients

1 reference

https://api.crossref.org/works/10.1002%2FLT.23935

21 January 2018

Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.

1 reference

https://api.crossref.org/works/10.1002%2FLT.23935

21 January 2018

Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcAb-positive grafts

1 reference

https://api.crossref.org/works/10.1002%2FLT.23935

21 January 2018

Type B fulminant hepatitis is closely associated with a highly mutated hepatitis B virus strain

1 reference

https://api.crossref.org/works/10.1002%2FLT.23935

21 January 2018

Coexistence of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of "a" determinant variants

1 reference

https://api.crossref.org/works/10.1002%2FLT.23935

21 January 2018

Vaccine-induced escape mutant of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1002%2FLT.23935

21 January 2018

Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact

1 reference

https://api.crossref.org/works/10.1002%2FLT.23935

21 January 2018

Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy

1 reference

https://api.crossref.org/works/10.1002%2FLT.23935

21 January 2018

Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy

1 reference

https://api.crossref.org/works/10.1002%2FLT.23935

21 January 2018

Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1002%2FLT.23935

21 January 2018

Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence

1 reference

https://api.crossref.org/works/10.1002%2FLT.23935

21 January 2018

Clinical and virological significance of the co-existence of HBsAg and anti-HBs antibodies in hepatitis B chronic carriers

1 reference

https://api.crossref.org/works/10.1002%2FLT.23935

21 January 2018

Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy

1 reference

https://api.crossref.org/works/10.1002%2FLT.23935

21 January 2018

Identifiers

10.1002/LT.23935

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42210316&oldid=1936002882"